Hutchmed (China) Limited

Net Asset Value • Dec 29, 2014

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 8020A

Hutchison China Meditech Limited

29 December 2014

Hutchison China MediTech Limited ("Chi-Med")

(AIM: HCM)

Blocklisting Six Monthly Return

London: Monday, 29 December 2014: Chi-Med announces the following blocklisting six monthly return:

1.	Name of applicant:		Hutchison China MediTech Limited
2.	Name of scheme:		Hutchison China MediTech Limited Share Option Scheme
3.	Period of return:		From 29 June 2014 to 28 December 2014
4.	Balance under scheme from previous return:		876,279 ordinary shares of US$1 each
5.	The amount by which the block scheme has been increased, if the scheme has been increased since the date of the last return:		Nil
6.	Number of securities issued/allotted under scheme during period:		180,228 ordinary shares of US$1 each
7.	Balance under scheme not yet issued/allotted at end of the period:		696,051 ordinary shares of US$1 each
8.	Number and class of securities originally listed and the date of admission:		2,560,606 ordinary shares of US$1 each admitted on 26 June 2007
9.	Total number of securities in issue at the end of the period:		53,076,676 ordinary shares of US$1 each
Name of contact:			Christian Hogg
Address of contact:			21/F., Hutchison House, 10 Harcourt Road, Hong Kong
Telephone number of contact:			+852 2121 8200

Ends

Enquiries

Chi-Med Christian Hogg, CEO	Telephone:      +852 2121 8200
Panmure Gordon (UK) Limited	Telephone:      +44 20 7886 2500
Richard Gray Andrew Potts
Citigate Dewe Rogerson Anthony Carlisle David Dible	Telephone:      +44 20 7638 9571 Mobile:             +44 7973 611 888 Mobile:             +44 7967 566 919

About Chi-Med

Chi-Med is a China-based healthcare group focused on researching, developing, manufacturing and selling pharmaceuticals and health-related consumer products.  Its China Healthcare Division manufactures, markets and distributes prescription and over-the-counter pharmaceuticals in China.  Its Drug R&D Division focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases.  Its emerging Consumer Products Division focuses on organic and natural consumer products in Asia.

Chi-Med is majority owned by the multinational conglomerate Hutchison Whampoa Limited (SEHK:13).  For more information, please visit: www.chi-med.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

BLRUKUNRSUAUURA